Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer

Tim M. van der Sluis(Amsterdam UMC Location Vrije Universiteit Amsterdam), André N. Vis(Hôpitaux Universitaires Henri-Mondor), John J. L. Jacobs(Amsterdam UMC Location Vrije Universiteit Amsterdam), Lawrence Rozendaal(Amsterdam UMC Location Vrije Universiteit Amsterdam), Albert A. Geldof(Amsterdam UMC Location VUmc), R. Jeroen A. van Moorselaar(Amsterdam UMC Location Vrije Universiteit Amsterdam), E.J.H. Meuleman(Amsterdam UMC Location Vrije Universiteit Amsterdam), Irene V. Bijnsdorp(Amsterdam UMC Location Vrije Universiteit Amsterdam)
World Journal of Urology
October 18, 2012
10.1007/s00345-012-0972-4
Cited by 5

Related Papers

Nontemplated Nucleotide Additions Distinguish the Small RNA Composition in Cells from Exosomes
|Cell Reports|2014|592
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
|European Urology|2018|577
Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles
|Journal of Extracellular Vesicles|2021|410
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|357
Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome
|Journal of Clinical Oncology|2003|321